Biotech IPO Gains Crush AI Listings With Standout 55% Return

US biotech and pharmaceutical IPOs have delivered a weighted average return of about 55% in 2026, in sharp contrast to the 4.4% weighted average loss across the broader US IPO market. Biotech IPO proceeds have topped $5 billion this year, three times last year's tally, with rare cancer specialist Parabilis Medicines raising $770.6 million in the biggest-ever biotech listing, while Veradermics is up over 500% since its February debut. Big pharma acquisitions by Abbvie, GSK, and Vertex have lifted valuations, though higher-for-longer interest rates remain a potential headwind.